Annexin A1-FPR1 Interaction in dendritic cells promotes immune microenvironment modulation in Thyroid Cancer.

IF 5.9 2区医学 Q2 CELL BIOLOGY

Cell Biology and Toxicology Pub Date : 2025-06-07 DOI:10.1007/s10565-025-10042-6

Hongwei Jiang, Lirun Kuang, Tianyi Zhang, Xupeng Zhao

{"title":"Annexin A1-FPR1 Interaction in dendritic cells promotes immune microenvironment modulation in Thyroid Cancer.","authors":"Hongwei Jiang, Lirun Kuang, Tianyi Zhang, Xupeng Zhao","doi":"10.1007/s10565-025-10042-6","DOIUrl":null,"url":null,"abstract":"<p><p>Thyroid cancer (THCA) is profoundly influenced by its immune microenvironment, with dendritic cells (DCs) serving as key mediators of tumor-immune interactions. This study leveraged single-cell RNA sequencing and transcriptome RNA sequencing to analyze DC populations in THCA tissues. The results revealed significant disparities in DC distribution and function, with formyl peptide receptor 1 (FPR1) emerging as a crucial factor associated with patient prognosis. Meta-analysis further validated the differential expression of FPR1, reinforcing its significance in THCA progression. Investigations into the TME highlighted the relationship between FPR1 and DC maturation and activation, elucidating the mechanistic basis for immune regulation. Experimental validation confirmed that Annexin A1 (ANXA1) interacts with FPR1 in DCs, promoting tumor progression through immune modulation. These findings advance the understanding of THCA immune mechanisms and underscore the potential of targeting the ANXA1-FPR1 axis as a novel approach for immunotherapy in THCA.</p>","PeriodicalId":9672,"journal":{"name":"Cell Biology and Toxicology","volume":"41 1","pages":"97"},"PeriodicalIF":5.9000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145322/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Biology and Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10565-025-10042-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Thyroid cancer (THCA) is profoundly influenced by its immune microenvironment, with dendritic cells (DCs) serving as key mediators of tumor-immune interactions. This study leveraged single-cell RNA sequencing and transcriptome RNA sequencing to analyze DC populations in THCA tissues. The results revealed significant disparities in DC distribution and function, with formyl peptide receptor 1 (FPR1) emerging as a crucial factor associated with patient prognosis. Meta-analysis further validated the differential expression of FPR1, reinforcing its significance in THCA progression. Investigations into the TME highlighted the relationship between FPR1 and DC maturation and activation, elucidating the mechanistic basis for immune regulation. Experimental validation confirmed that Annexin A1 (ANXA1) interacts with FPR1 in DCs, promoting tumor progression through immune modulation. These findings advance the understanding of THCA immune mechanisms and underscore the potential of targeting the ANXA1-FPR1 axis as a novel approach for immunotherapy in THCA.

查看原文本刊更多论文

树突状细胞中的膜联蛋白A1-FPR1相互作用促进甲状腺癌免疫微环境调节。

甲状腺癌（THCA）受其免疫微环境的深刻影响，树突状细胞（dc）是肿瘤-免疫相互作用的关键介质。本研究利用单细胞RNA测序和转录组RNA测序来分析THCA组织中的DC群体。结果显示DC分布和功能存在显著差异，甲酰基肽受体1 （FPR1）成为与患者预后相关的关键因素。meta分析进一步验证了FPR1的差异表达，强化了其在THCA进展中的意义。对TME的研究强调了FPR1与DC成熟和激活之间的关系，阐明了免疫调节的机制基础。实验证实，在dc中，膜联蛋白A1 （ANXA1）与FPR1相互作用，通过免疫调节促进肿瘤进展。这些发现促进了对THCA免疫机制的理解，并强调了靶向ANXA1-FPR1轴作为THCA免疫治疗新方法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Biology and Toxicology 生物-毒理学

CiteScore

9.90

自引率

4.90%

发文量

101

审稿时长

>12 weeks

期刊介绍： Cell Biology and Toxicology (CBT) is an international journal focused on clinical and translational research with an emphasis on molecular and cell biology, genetic and epigenetic heterogeneity, drug discovery and development, and molecular pharmacology and toxicology. CBT has a disease-specific scope prioritizing publications on gene and protein-based regulation, intracellular signaling pathway dysfunction, cell type-specific function, and systems in biomedicine in drug discovery and development. CBT publishes original articles with outstanding, innovative and significant findings, important reviews on recent research advances and issues of high current interest, opinion articles of leading edge science, and rapid communication or reports, on molecular mechanisms and therapies in diseases.